Novo Nordisk Sues to Block Pharmacy-Made Versions of Wegovy

Novo sues US compounding pharmacy making and selling versions of semaglutide, the active ingredient in the company’s blockbuster weight-loss drug Wegovy.

• Compounding pharmacy is violating state law by selling drugs that lack Food and Drug Administration approval and haven’t been sufficiently studied, Novo says in suit filed Thursday in Florida federal court.
• Brooksville didn’t immediately respond to a request for comment.

To contact the reporter on this story:
Emma Court in New York at ecourt1@bloomberg.net

To contact the editors responsible for this story:
Catherine Larkin at clarkin4@bloomberg.net

John Lauerman

© 2023 Bloomberg L.P. All rights reserved. Used with ...